A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Columbia University
Duke University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of Pittsburgh
Bolt Biotherapeutics, Inc.
M.D. Anderson Cancer Center
Maastricht University Medical Center
Palleon Pharmaceuticals, Inc.
Columbia University
Regeneron Pharmaceuticals
Vyriad, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Jules Bordet Institute